Newsfeeds - Spark Newswire

1 minute read

CORRECTED: JP Morgan Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $17 – Rating Updated

Today, 8:41 AM

CORRECTED: JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $19 to $17, rating updated.

ACAD

1 minute read

JP Morgan Maintains Overweight on ACADIA Pharmaceuticals, Lowers Price Target to $17

By Benzinga Newsdesk

Today, 8:41 AM

JP Morgan analyst Tessa Romero maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Overweight and lowers the price target from $19 to $17.

ACAD

1 minute read

Goldman Sachs Downgrades ACADIA Pharmaceuticals to Sell, Lowers Price Target to $12

By Benzinga Newsdesk

Today, 8:41 AM

Goldman Sachs analyst Salveen Richter downgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) from Neutral to Sell and lowers the price target from $15 to $12.

ACAD

4 minute read

Important Biotech Catalysts For September 12, 2022 – End Of The Day Summary

By Ragothaman Srinivasan

Today, 8:41 AM

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mersana Therapeutics’ (NASDAQ:MRSN) lead candidate…

ACAD

1 minute read

U.S. FDA Accepts Acadia’s Filing For Rett Syndrome Candidate Under Priority Review

By Ragothaman Srinivasan

Today, 8:41 AM

The U.S. Food and Drug Administration (FDA) has accepted for filing Acadia Pharmaceuticals’ (NASDAQ: ACAD) New Drug Application (NDA) of trofinetide for the treatment of Rett syndrome. The regulatory agency has granted a priority review and assigned a PDUFA action date of March 12, 2023.

ACAD

6 minute read

Bluebird bio Seeks Back-to-Back Nods, ‘Go’ or ‘No-Go’ For Revance’s Botox Rival, Amylyx’ Twin Hurdles And More: September’s Key PDUFA Catalysts Biotech Investors Must Know

By Shanthi Rexaline

Today, 8:41 AM

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.

ACAD

1 minute read

Goldman Sachs Maintains Neutral on ACADIA Pharmaceuticals, Lowers Price Target to $15

By Benzinga Newsdesk

Today, 8:41 AM

Goldman Sachs analyst Salveen Richter maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Neutral and lowers the price target from $20 to $15.

ACAD

1 minute read

Acadia Terminates Painkiller, Cancer Candidate After Disappointing Data

By Vandana Singh

Today, 8:41 AM

Acadia Pharmaceuticals Inc (NASDAQ:ACAD) stopped working on two candidates, including a one-time competitor to Vertex Pharmaceuticals Incorporated’s (NASDAQ:VRTX) non-opioid painkiller. The company…

ACAD

1 minute read

ACADIA Pharmaceuticals Faces Several Price Target Cuts After Q2 Results, But This Analyst Disagrees

By Lisa Levin

Today, 8:41 AM

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) reported upbeat results for its second quarter after the closing bell on Monday.

ACAD

1 minute read

NVIDIA To $240? Here Are 5 Other Price Target Changes For Tuesday

By Lisa Levin

Today, 8:41 AM

Raymond James cut the price target on NVIDIA Corporation (NASDAQ: NVDA) from $250 to $240. Raymond James analyst Melissa Fairbanks maintained the stock with a Strong Buy. NVIDIA shares fell 2.8% to $172.92 in pre-market trading.

ACAD